Korean Market
FTC
Celltrion
★

Celltrion Files Annual Corporate Group Disclosure: Stable Financials, Continued Share Buyback and Cancellation

 
EXCH
Celltrion
★★

Celltrion Discloses Corporate Governance Report: Achieves 103% Shareholder Return Rate with 2.86T KRW Share Cancellation and 750 KRW Dividend

 
OWNR
Celltrion
★

Celltrion Executive Vice President Choe Byeong-seo Sells All 3,000 Shares via Open Market... Limited Impact on Shareholder Value Due to Small Scale

 
EXCH
Celltrion
★★

Celltrion submits marketing authorization for CT-P6 SC (Herzuma subcutaneous) in Korea; Phase 1 success signals expanded breast cancer treatment options and enhanced enterprise value

 
MATR
Celltrion
★

Free Stock Distribution of 10,920,342 Shares (0.05 per Share)

 
MATR
Celltrion
★

Celltrion to Acquire KRW 100 Billion Worth of Treasury Shares for Price Stabilization and Shareholder Value Enhancement

 
OWNR
Celltrion
★★

Celltrion Holdings Plans to Purchase Celltrion Shares Worth 100 Billion Won

 
PERI
Celltrion
★★★

Celltrion Q1 2026 Strong Results, Enhanced Shareholder Returns via Share Cancellation and Dividend

 
EXCH
Celltrion
★

CT-P55 (Cosentyx Biosimilar) US Phase 3 Trial Plan Amendment Approved by FDA

 
EXCH
Celltrion
★

Celltrion USA Amends Rights Offering: Total Amount Reduced, Second Payment Date Set

 
EXCH
Celltrion
★

Celltrion Invests Additional 516.1M USD in Subsidiary Celltrion USA

 
OTHR
Celltrion
★

Celltrion Reports Completion of Treasury Stock Acquisition

 
EXCH
Celltrion
★★★★

Decision to Cancel 488,977 Treasury Shares within Distributable Profits

 
EXCH
Celltrion
★★

Celltrion Q1 2026 Operating Profit 321.9 Billion Won... Up 115% YoY

 
EXCH
Celltrion
★★★★

Decision to Cancel 488,983 Treasury Shares to Enhance Shareholder Value